- CEO
- Chi Hong Chen
- Full Time Employees
- 29,695
- Sector
- Electronic technology
- Industry
- Computer processing hardware
- Address
- 157 Shan-Ying Road Taoyuan Taiwan 333
- IPO Date
- Jul 22, 1996
- Business
- Qisda Corporation (2352.TW), established in 1984 and headquartered in Taoyuan City, Taiwan, serves as a global original design manufacturer and original equipment manufacturer of electronic products spanning consumer, commercial, industrial, medical, and automotive applications; its core offerings encompass high-end and professional displays for gaming, graphics, broadcasting, and medical uses; optical precision electronics including projectors and automotive infotainment devices; industrial and commercial computers with peripherals such as POS printers, barcode scanners, thermal cameras, and automated guided vehicles; medical equipment, consumables, digital dentistry solutions, dialysis systems, and hearing aids; smart solutions for enterprises, manufacturing, retail, campuses, healthcare, and energy management; as well as 5G enterprise private networks, wired and wireless broadband products, and integrated maintenance services. The company operates manufacturing facilities in Taoyuan, Suzhou in China, and Ninh Binh in Vietnam, with R&D centers in Taoyuan and Suzhou, service locations in Japan, Singapore, and the USA, and global reach across over 100 countries through subsidiaries in more than 28 nations. Qisda maintains world-leading positions in LCD monitors and projectors while owning two large general hospitals under BenQ Medical Centers and advancing high-value-added segments through its grand fleet strategy. In recent developments, Qisda completed the acquisition of an additional 13.95% stake in Norbel Baby Co., Ltd. (TPEX:6844), operator of the Tin Tin Drugstore chain, in November 2024, boosting its ownership beyond 40% to enhance healthcare retail channels and elderly care offerings; the company also reported fiscal 2024 consolidated revenue of NT$201.7 billion with a record gross margin of 16.5%, proposed an 18% capital reduction for shareholder cash returns, and reaffirmed goals for high-value businesses like medical and smart solutions to exceed half of total profits by 2027 alongside net-zero emissions by 2050.